|Reviewer||Employment||Research Grant||Other Research Support||Speakers' Bureau/ Honoraria||Expert Witness||Ownership Interest||Consultant/ Advisory Board||Other|
|Elliott M. Antman||Brigham and Women's Hospital||Eli Lilly⁎||None||None||None||None||None||None|
|Gregory J. Dehmer||Texas A&M University College of Medicine and Scott & White Clinic||None||None||None||None||None||None||None|
|T. Bruce Ferguson||East Carolina University||None||None||None||None||None||None||None|
|Raymond J. Gibbons||Mayo Clinic||Radiant Medical,† KAI Pharmaceuticals,† TargeGen,† TherOx†||None||None||None||None||Hawaii Biotech,⁎ TIMI 37A⁎||None|
|Arthur H. Jeske||University of Texas Health Science Center, Houston||None||None||None||None||None||None||None|
|Vincenza Snow||American College of Physicians||None||None||None||None||None||None||None|
This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (1) the person receives $10 000 or more during any 12-month period or 5% or more of the person's gross income; or (2) the person owns 5% or more of the voting stock or share of the entity or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.